Ganesha, as much as I hate to say it, it looks like you're correct. But in the Dr. Jay interview doesn't it sound like compassionate use patients might be able to start ICI's sooner?

"00:30:10]: In the meantime we've started to enroll our Colorectal cancer study have a bunch of sites actively enrolling now and what we're going to be doing shortly is submitting a request to the FDA for a meeting at which point we're going to give them a rollover protocol for the Colorectal cancer patients that we're monitoring their PD-L1 status during the study and in the rollover protocol. We hope to then provide them a checkpoint inhibitor to see if we can replicate that clinical benefit, that survival benefit that we saw in the breast cancer patients.

[00:30:49]: At the same time, we're submitting a phase 2 follow-up protocol for the FDA in triple negative breast cancer. And then thirdly, we're going to be submitting a compassionate use protocol for triple negative breast cancer patients who are otherwise ineligible for our phase two study. And in that program as well, we'll be able to verify the induction of PD-L1 and then help those patients where we can to add in a checkpoint inhibitor."

https://www.reddit.com/r/Livimmune/comments/1...o_cytodyn/